Abstract:The use of epigenetic bromodomain inhibitors as anticancer therapeutics has transitioned from targeting bromodomain extraterminal domain (BET) proteins into targeting non-BET bromodomains. The two most relevant non-BET bromodomain oncology targets are cyclic AMP response element-binding protein (CBP) and E1A binding protein P300 (EP300). To explore the growing CBP/EP300 interest, we developed a highly efficient two-step synthetic route for dimethylisoxazole-attached imidazo[1,2-a]pyridine scaffold-containing inhibitors. Our efficient two-step reactions enabled high-throughput synthesis of compounds designed by molecular modeling, which together with structure–activity relationship (SAR) studies facilitated an overarching understanding of selective targeting of CBP/EP300 over non-BET bromodomains. This led to the identification of a new potent and selective CBP/EP300 bromodomain inhibitor, UMB298 (compound 23, CBP IC50 72 nM and bromodomain 4, BRD4 IC50 5193 nM). The SAR we established is in good agreement with literature-reported CBP inhibitors, such as CBP30, and demonstrates the advantage of utilizing our two-step approach for inhibitor development of other bromodomains.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02232?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02232</a>.Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_001.csv">CSV</a>)BromoSCAN, differential scanning fluorometry (DSF), and cellular activity data of compounds 7, 16, and 23; crystallographic data collection and refinement statistics of compound 23; 1H NMR and 13C NMR of representative compounds; and HPLC traces of compounds 7, 16, and 23 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_002.pdf">PDF</a>)Homology (docking) models of BRD4_5BT4_Cpd7 (UMB276) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_003.pdb">PDB</a>)Homology (docking) models of BRD4_5BT4_Cpd-16 (UMB295) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_004.pdb">PDB</a>)Homology (docking) models of BRD4_5BT4_Cpd-23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_005.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-3 (UMB274) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_006.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-4 (UMB278) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_007.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-7 (UMB276) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_008.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-16 (UMB295) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_009.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_010.pdb">PDB</a>)Cocrystallographic data of compound 23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_011.pdb">PDB</a>)This article has not yet been cited by other publications.

Positional Isomeric Effects on the Optical Properties, Multivalent Glycosidase Inhibition Effect, and Hypoglycemic Effect of Perylene Bisimide–deoxynojirimycin Conjugates

Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Multivalent Pyrrolidine Iminosugars: Synthesis and Biological Relevance

Fluorescence sensing and glycosidase inhibition effect of multivalent glycosidase inhibitors based on Naphthalimide-deoxynojirimycin conjugates

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Discovery of Pyrrole-imidazole Polyamides as PD-L1 Expression Inhibitors and Their Anticancer Activity via Immune and Nonimmune Pathways

Molecular Conformation and Aggregation Regulation of Bay. Substituted Perylene Bismides: Ortho-Methyl Steric Hindrance

Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives As Dipeptidyl Peptidase 4 Inhibitors.

Piceid dicarboxylic acid esters as potent α-glucosidase inhibitors and antiglycation agents: Synthesis, spectroscopic and molecular docking studies

One-pot domino synthesis of 1H-isochromene and pyran carbonitrile from pyrazole aldehyde derivatives as potential anti-diabetic and antioxidant targets

Integrative bioinformatic and experimental analysis of benzoylbenzodioxol derivatives: hypoglycemic potential in diabetic mice

Synthesis, molecular docking, enzyme inhibition and antioxidant potential of new 1H-benzo[ d ]imidazole-5-carboxamide derivatives

In vitro α-amylase and α-glucosidase inhibition study of dihydropyrimidinones synthesized via one-pot Biginelli reaction in the presence of a green catalyst

Development of Dimethylisoxazole-Attached Imidazo[1,2- a ]pyridines as Potent and Selective CBP/P300 Inhibitors

Synthesis and Evaluation of Phenyltriazole-Deoxynojirimycin Hybrids as Potent α-Glucosidase Inhibitors

Supramolecular azasugar clusters based on an amphiphilic fatty-acid-deoxynojirimycin derivative as multivalent glycosidase inhibitors

Synthesis, α-Glucosidase, α-Amylase, and Aldol Reductase Inhibitory Activity with Molecular Docking Study of Novel Imidazo[1,2- a ]pyridine Derivatives

Design, synthesis and enzymatic inhibition evaluation of novel 4-Hydroxy Pd-C-III derivatives as α-glucosidase and PTP1B dual-target inhibitors

Structure-Based Design of Marine-derived Meridianin C Derivatives As Glycogen Synthase Kinase 3β Inhibitors with Improved Oral Bioavailability: from Aminopyrimidyl-Indoles to the Sulfonyl Analogues

Synthesis and Biological Activity of Novel Deoxynojirimycin Derivatives As Potent Alpha-Glucosidase Inhibitors